[1]游慧娟,吴阳洋,欧阳桂兰,等.固本平喘方对COPD模型大鼠NF-κB p65、IKBα、IL-1β mRNA表达的影响[J].陕西中医,2025,46(10):1305-1311.[doi:DOI:10.3969/j.issn.1000-7369.2025.10.002]
　YOU Huijuan,WU Yangyang,OUYANG Guilan,et al.Effects of Guben Pingchuan formula on the expression of NF-κB p65,IKBα,and IL-1β mRNA in a rat model of chronic obstructive pulmonary disease[J].,2025,46(10):1305-1311.[doi:DOI:10.3969/j.issn.1000-7369.2025.10.002]
点击复制

固本平喘方对COPD模型大鼠NF-κB p65、IKBα、IL-1β mRNA表达的影响

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
46
期数:
2025年10期
页码:
1305-1311
栏目:
基础研究
出版日期:
2025-10-05

文章信息/Info

Title:
Effects of Guben Pingchuan formula on the expression of NF-κB p65,IKBα,and IL-1β mRNA in a rat model of chronic obstructive pulmonary disease
作者:
游慧娟1; 吴阳洋1; 欧阳桂兰1; 陈新海2; 游柏稳1
（1.湖南中医药大学第二附属医院,湖南 长沙 410005;2.道县人民医院,湖南 永州 425300）
Author(s):
YOU Huijuan1; WU Yangyang1; OUYANG Guilan1; CHEN Xinhai2; YOU Bowen1
(1.The Second Affiliated Hospital of Hunan University of Traditional Chinese Medicine,Changsha 410005,China;2.Daoxian People’s Hospital,Yongzhou 425300,China)
关键词:
慢性阻塞性肺疾病; 固本平喘方; 大鼠; 核因子-κB p65; 炎症; 人核因子κB抑制蛋白α
Keywords:
Chronic obstructive pulmonary disease; Guben Pingchuan formula; Rats; Nuclear factor kappa-B p65 subunit; Inflammation; Inhibitor of nuclear factor kappa-B alpha
分类号:
R 563
DOI:
DOI:10.3969/j.issn.1000-7369.2025.10.002
文献标志码:
A
摘要:
目的：研究核因子-κB p65(NF-κB p65)、人核因子κB抑制蛋白α(IKBα)、白细胞介素-1β的信使RNA(IL-1β mRNA)在慢性阻塞性肺疾病（COPD）模型大鼠中的表达，以探讨固本平喘方对大鼠COPD的治疗作用及相关分子机制。方法：将64只SPF级SD大鼠适应性饲养1周后，随机选52只用来造模，剩余12只为空白组。空白组不做处理，剩余大鼠用香烟烟雾暴露及气管滴注脂多糖(LPS)、聚苯醚(PPE)造模，待造模成功后，在52只大鼠中随机选取50只分为：模型组、地塞米松组（0.15 mg/kg）、固本平喘方高（28 g/kg）、中（14 g/kg）、低（7 g/kg）剂量组，每组各10只。空白组中同样随机选取10只。15 d后让大鼠安乐死并采集所需标本，在HE染色下观察大鼠肺组织病理学改变；以酶联免疫吸附测定（ELISA）法测定肺组织中炎症因子IL-1β水平；Western blot实验检测肺组织NF-κB p65、IKBα蛋白表达，免疫荧光检测其分布态势；RT-PCR检测肺组织中IL-1β mRNA的相对表达量。结果：模型组大鼠肺组织结构明显受损，肺泡腔及肺间质可见大量炎性浸润；地塞米松组及固本平喘方各剂量组炎性浸润程度较模型组相比减轻。与空白组对比，其余各组肺组织中IL-1β含量、NF-κB p65表达均升高（P＜0.05），IKBα含量均降低（P＜0.05）；与模型组比较，地塞米松组及固本平喘方各剂量组IL-1β含量、NF-κB p65表达及IL-1β mRNA表达均降低（P＜0.05），IKBα表达均升高（P＜0.05）；固本平喘方高剂量组较低剂量组IL-1β含量、NF-κB p65表达及IL-1β mRNA表达降低（P＜0.05），IKBα表达升高（P＜0.05）。肺组织免疫荧光结果显示，NF-κB p65在模型组中呈强表达，在固本平喘方低剂量组表现为较强荧光，且随着固本平喘方剂量增加，免疫荧光逐渐减弱。结论：固本平喘方可降低COPD模型大鼠肺组织中NF-κB p65蛋白表达及IL-1β含量，升高IKBα的蛋白表达，下调IL-1β mRNA表达，减轻大鼠气道炎症反应，继而降低COPD模型大鼠肺组织损伤，以达到保护COPD模型大鼠肺脏的作用。
Abstract:
Objective:This study investigated the therapeutic potential and molecular mechanisms of Guben Pingchuan formula in COPD rats by analyzing NF-κB p65,IKBα,and IL-1β expression.Methods:Sixty-four SPF SD rats underwent 1-week acclimatization,with 52 subjected to COPD modeling via cigarette smoke exposure combined with intratracheal LPS and PPE instillation.Twelve untreated rats served as the blank group.Post-modeling,50 rats were randomized into five cohorts (n=10/group):model group,dexamethasone group (0.15 mg/kg),and the Guben Pingchuan formula High (28 g/kg),Medium (14 g/kg),and Low (7 g/kg) dosage groups.Ten blank group rats were randomly included.After 15 days,samples were collected post-euthanasia for:observing the histopathological changes in the lungs of rats by HE staining;to determine the level of the inflammatory factor IL-1β in the lung tissues by ELISA;western blot and immunofluorescence analysis of NF-κB p65 and IKBα protein expression.The relative expression of IL-1β mRNA in lung tissue was sensed using RT-PCR.Results:The model group showed that severe alveolar and interstitial tissue were damaged with inflammatory cell infiltration,while dexamethasone and GPF groups exhibited attenuated pathology.Compared to the blank group,elevated IL-1β levels (P<0.05) and NF-κB p65 expression (P<0.05) accompanied by reduced IκBα (P<0.05) were detected in other groups.Conversely,GPF and dexamethasone treatments significantly suppressed IL-1β,NF-κB p65,and IL-1β mRNA expression (P<0.05),while upregulating IKBα (P<0.05).Dose-dependent effects were evident:high-dose GPF showed stronger inhibition of inflammatory markers and higher IKBα induction than low-dose (P<0.05).Immunofluorescence results indicated that NF-κB p65 was strongly expressed in the model group and showed stronger fluorescence in the low-dose group of Guben Pingchuan formula.It was gradually weakened across Guben Pingchuan formula dose gradients.Conclusion:Guben Pingchuan formula can reduce NF-κB p65 protein expression and IL-1β content,increase IKBα protein expression,and down-regulate IL-1β mRNA expression in the lung tissues of rats with COPD,thereby mitigating pulmonary inflammation and tissue damage.

参考文献/References:

[1]杨洋,李竹英,田春燕,等.中医药干预慢性阻塞性肺疾病相关信号通路的研究进展[J].中国实验方剂学杂志,2024,30(15):244-255.
[2]郭霭春.黄帝内经灵枢校释[M].北京：中国中医药出版社，2021：861.
[3]吴蕾,郑俐慈,陈远彬,等.基于宗气、元气理论探讨慢性阻塞性肺疾病的病机与辨治[J].中医杂志,2023,64(14):1440-1443.
[4]赵正阳,王至婉.肺气虚为慢性阻塞性肺疾病稳定期病机根本及其与肺功能之间的关系[J].中华中医药学刊,2022,40(11):161-164.
[5]丁健,陶慧,程刚,等.韩明向分期分证治疗慢性阻塞性肺疾病经验[J].中医杂志,2025,66(8):780-785.
[6]徐桂铃,龚钊乾,王珺娆,等.2型炎症对COPD大、小气道支气管舒张反应性的不同影响[J].南方医科大学学报,2024,44(1):93-99.
[7]何军頵,申永春,吴艳秋,等.血清白介素-19水平与慢性阻塞性肺疾病患者临床表型、肺功能和系统性炎症的相关性研究[J].四川大学学报(医学版),2019,50(3):438-440.
[8]张林,徐厚平,刘代群,等.黄芩素调控TLR4/NF-κB通路对慢性阻塞性肺疾病大鼠气道炎症的影响[J].中国免疫学杂志,2025,41(4):903-907.
[9]胡啸博,周哲旭,菅佳宁,等.中性粒细胞胞外诱捕网与慢性阻塞性肺疾病发病机制关系的研究进展[J].中国老年学杂志,2025,45(8):2026-2032.
[10]HOU W,HU S,LI C,et al.Cigarette smoke induced lung barrier dysfunction,EMT,and tissue remodeling:A possible link between COPD and lung cancer[J].Biomed Res Int,2019,2019:2025636.
[11]OSEI E T,BRANDSMA C A,TIMENS W,et al.Current perspectives on the role of interleukin-1 signalling in the pathogenesis of asthma and COPD[J].Eur Respir J,2020,55(2):1900563.
[12]ZHANG M,LU Y,LIU L,et al.Role and mechanism of miR-181a-5p in mice with chronic obstructive pulmonary disease by regulating HMGB1 and the NF-κB pathway[J].Cells Tissues Organs,2023,212(3):245-257.
[13]GUDOWSKA S M,MROCZKO B.The role of nuclear factor kappa B (NF-κB) in development and treatment of COVID-19:Review[J].Int J Mol Sci,2022,23(9):5283.
[14]KESIKA P,THANGALEELA S,SISUBALAN N,et al.The role of the nuclear factor-kappa B (NF-κB) pathway in SARS-CoV-2 infection[J].Pathogens,2024,13(2):164.
[15]CHEN P,RUAN A,ZHOU J,et al.Cinnamic aldehyde inhibits lipopolysaccharide-induced chondrocyte iInflammation and reduces cartilage degeneration by blocking the nuclear factor-kappa B signaling pathway[J].Front Pharmacol,2020,11:949.
[16]HUXFORD T,HUANG D B,MALEK S,et al.The crystal structure of the Ikappa balpha/NF-kappa B complex reveals mechanisms of NF-kappa B inactivation[J].Cell,1998,95(6):759-770.
[17]欧阳桂兰.基于Notch通路探讨固本平喘方对慢性阻塞性肺疾病稳定期大鼠气道黏液高分泌的影响[D].长沙:湖南中医药大学,2023.
[18]曾星凝,游柏稳,吴阳洋,等.基于Wnt/β-catenin信号通路探讨固本平喘方对COPD大鼠Wnt1、β-catenin表达的影响[J].山西中医药大学学报,2025,26(3):259-264.
[19]欧阳桂兰,游柏稳.慢性阻塞性肺疾病大鼠模型的建立与比较[J].中西医结合研究,2023,15(2):86-90.
[20]卢心鹏,刘蓉,黄文博,等.不同方法建立大鼠慢性阻塞性肺疾病模型的比较研究[J].实验动物与比较医学,2022,42(3):201-206.
[21]CHRISTENSON S A,SMITH B M,BAFADHEL M,et al.Chronic obstructive pulmonary disease[J].Lancet,2022,399(10342):2227-2242.
[22]吴阳洋,欧阳桂兰,陈新海,等.固本平喘方对慢性阻塞性肺疾病模型大鼠气道MUC5AC水平的影响 [J].湖南中医药大学学报,2024,44(4):565-571.
[23]李仪奎.中药药理实验方法学[M].上海:上海科学技术出版社,2006:1088.
[24]PATEL N.An update on COPD prevention,diagnosis,and management:The 2024 GOLD report[J].Nurse Pract,2024,49(6):29-36.
[25]罗倩,符蕤,彭博,等.基于16S rDNA技术探讨痰热清注射液对COPD模型大鼠肺部菌群的影响[J].中国实验方剂学杂志,2024,30(23):98-103.
[26]李坤朋,唐志宇,邓杰强,等.中医药对慢性阻塞性肺疾病炎症反应相关信号通路交汇作用的研究进展[J].中国医药科学,2025,15(7):48-51.
[27]邹吉宇,王天娇,臧凝子,等.慢性阻塞性肺疾病发病机制及中药调节作用研究进展[J].中国实验方剂学杂志,2025,31(1):287-298.
[28]孙辉.肺胀源流探析[J].中医药学报,2008,15(1):7-9.
[29]段亚娟,张翠娟.吸入性糖皮质激素治疗嗜酸性粒细胞增高COPD急性加重期患者的临床效果[J].临床医学工程,2024,31(8):937-938.
[30]陈典,隆寰宇,张丛溪,等.2025年GOLD慢性阻塞性肺疾病诊断、治疗、管理及预防全球策略更新要点解读[J].中国全科医学,2025,28(16):1937-1949.
[31]LIU L,ZHOU L,WANG L,et al.MUC1 attenuates neutrophilic airway inflammation in asthma by reducing NLRP3 inflammasome-mediated pyroptosis through the inhibition of the TLR4/MyD88/NF-κB pathway[J].Respir Res,2023,24(1):255.
[32]WANG J,LI R,PENG Z,et al.HMGB1 participates in LPSinduced acute lung injury by activating the AIM2 inflammasome in macrophages and inducing polarization of M1 macrophages via TLR2,TLR4,and RAGE/NF-κB signaling pathways[J].Int J Mol Med,2020,45(1):61-80.
[33]梁晔,庄洁,房晓华,等.茯苓甘草合剂辅助西药对慢性阻塞性肺疾病合并肌肉衰减患者NF-κB信号通路的影响[J].河北医药,2024,46(2):196-200.
[34]HUAN W,TIANZHU Z,YU L,et al.Effects of ergosterol on COPD in mice via JAK3/STAT3/NF-κB pathway[J].Inflammation,2017,40(3):884-893.

相似文献/References:

[1]杨栓柱,王 文 △,李 猛,等.千金苇茎汤合瓜蒌薤白杏仁汤治疗 慢性阻塞性肺疾病急性加重期临床研究*[J].陕西中医,2019,(5):600.
[2]王 敏,陈 阁.清热化痰祛瘀方联合西药治疗慢性阻塞性肺疾病急性 加重期患者的临床研究[J].陕西中医,2019,(5):610.
　WANG Min,CHEN Ge..Clinical study of Qingre Huatan Quyu prescription combined with western medicine in the treatment of acute exacerbation of chronic obstructive pulmonary disease[J].,2019,(10):610.
[3]李天浩,韩晨旭,王惠琴,等.基于EGFR-MUC5AC信号通路探讨参鱼化痰口服液干预慢性阻塞性肺疾病大鼠气道黏液高分泌的机制*[J].陕西中医,2019,(8):995.
　LI Tianhao,HAN Chenxu,WANG Huiqin,et al.Based on EGFR-MUC5AC signaling pathway to explore the mechanism of Shenyu Huatan oral liquid in intervention of airway mucus high secretion in COPD rats[J].,2019,(10):995.
[4]王珊珊,谭光波△.补肺汤对慢性阻塞性肺疾病肺气肿大鼠血清IFNγ、IL4表达水平影响研究*[J].陕西中医,2019,(11):1491.
　WANG Shanshan,TAN Guangbo..Effect of Bufei decoction on the expression of IFNγ and IL4 in serum of rats with chronic obstructive pulmonary disease and emphysema[J].,2019,(10):1491.
[5]任英杰,王 起,陈秋生.黄芪汤加减治疗急性加重期慢性阻塞性肺疾病疗效研究[J].陕西中医,2020,(1):57.
　REN Yingjie,WANG Qi,CHEN Qiusheng..Observation on the curative effect of Huangqi decoction in the treatment ofacute exacerbation of chronic obstructive pulmonary disease[J].,2020,(10):57.
[6]聂清华,范伏元△.射干麻黄汤联合沙丁胺醇对慢性阻塞性肺疾病患者肺功能、生活质量的影响[J].陕西中医,2020,(2):180.
　NIE Qinghua,FAN Fuyuan..Effects of Shegan Mahuang decoction and albuterol on pulmonary function and quality of life in patients with COPD[J].,2020,(10):180.
[7]刘新平,王展儒.理肺化痰通脉方治疗慢性阻塞性肺疾病急性加重期临床研究[J].陕西中医,2020,(4):484.
[8]杜沂岚,唐 敏,陈朝晖△,等.经肺腧穴中药离子导入联合振动排痰治疗慢性阻塞性肺疾病急性加重期临床疗效*[J].陕西中医,2020,(4):534.
　DU Yilan,TANG Min,CHEN Zhaohui,et al.Clinical efficacy of Chinese medicine iontophoresis via Feishu point combined with vibration sputum discarding in the treatment of AECOPD[J].,2020,(10):534.
[9]唐颖丽,谢 珊,余清萍,等.子午流注法治疗慢性阻塞性肺疾病加重期痰浊阻肺证疗效研究*[J].陕西中医,2020,(9):1311.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.039]
　TANG Yingli,XIE Shan,YU Qingping,et al.Curative effect of midnight-noon ebb-flow method on chronic obstructive pulmonary disease exacerbation with syndrome of Tanzhuo Zufei[J].,2020,(10):1311.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.039]
[10]蔡东林,孙钟和,赵益庆.慢性阻塞性肺疾病稳定期BODE指数、IL-8、TNF-α水平与肺肾气虚证相关性研究*[J].陕西中医,2020,(11):1573.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.015]

备注/Memo

备注/Memo:
湖南省中医药管理局重点项目（2021003）
更新日期/Last Update: 2025-10-10